抗生素使用与头颈部鳞癌免疫检查点抑制剂疗效的关系
该回顾性研究纳入2015至2025年间治疗的316例复发/转移性头颈部鳞癌患者,评估抗生素暴露与免疫检查点抑制剂(ICI)疗效的关系。结果显示46.8%患者在接受ICI前后使用过抗生素,抗生素暴露与总生存期(OS)下降相关(HR=1.53,95%CI 1.15-2.04)。多因素分析中,口服 cavity 部位、ECOG 2-4、PD-L1 CPS<1及抗生素种类数量为独立不良预后因素。
要点
- 抗生素暴露与ICI治疗的HNSCC患者OS降低相关(HR=1.53)。
- 口服 cavity 部位、ECOG 2-4、PD-L1 CPS<1及抗生素种类数量独立预测OS下降。
- 抗生素给药途径和抗菌谱未显示为风险因素。
核心结论
- 抗生素暴露与接受ICI治疗的HNSCC患者生存期缩短相关,但需未来研究探讨潜在机制。
研究设计与样本
- 回顾性研究,纳入2015至2025年间治疗的316例复发/转移性HNSCC患者,中位年龄68岁,70.9%为男性。
主要发现
- 多因素分析显示口服 cavity 部位(HR=1.72,95%CI 1.07-2.76)、ECOG 2-4(HR=2.78,95%CI 1.70-3.67)、PD-L1 CPS<1(HR=3.16,95%CI 1.79-5.04)及抗生素种类数量(HR=1.37,95%CI 1.18-1.59)独立预测OS降低。
- 静脉给药途径和抗菌谱未显示为风险因素。
临床怎么用
- 在HNSCC患者接受ICI治疗时,应关注抗生素暴露史,尤其是口服 cavity 部位、ECOG 2-4、PD-L1 CPS<1及使用多种抗生素的患者可能预后更差。
局限性
- 回顾性研究设计,需未来研究评估该关联的潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical relevance of antibiotic exposure on immune checkpoint inhibitor (ICI) efficacy in head and neck squamous cell carcinoma (HNSCC) is not well characterized. METHODS: This retrospective study included patients with recurrent/metastatic HNSCC treated between 2015 and 2025. Cox proportional hazards and Kaplan-Meier method modeled overall survival (OS). RESULTS: Of 316 patients (median age 68 years, 70.9% male), primary tumor site was 40.5% oral cavity, 34.8% oropharynx, 14.9% sinonasal/nasopharynx, 9.8% hypopharynx/larynx. One hundred and forty-eight (46.8%) patients received antibiotics surrounding ICI. Antibiotics were associated with decreased OS (HR = 1.53, 95% CI 1.15-2.04). On multivariable analysis, while intravenous route of administration and spectrum of antibiotic activity were not risk factors, oral cavity site (HR = 1.72, 95% CI 1.07-2.76), ECOG 2-4 (HR = 2.78, 95% CI 1.70-3.67), PD-L1 CPS < 1 (HR = 3.16, 95% CI 1.79-5.04), and number of antibiotic classes (HR = 1.37, 95% CI 1.18-1.59) independently predicted decreased OS. CONCLUSIONS: Antibiotic exposure was associated with decreased survival in HNSCC treated with ICI; however, future studies are needed to evaluate potential mechanistic etiologies underlying this association.
引用
- Wu SS, Divi V, Sunwoo JB, et al. Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma. Head Neck. 2026. PMID: 42458796. doi:10.1002/hed.70392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。